P1422

Low incidence of major procedure-related adverse events of cryoballoon ablation in real practice: an interim analysis of the Russian national prospective cryoablation registry

Lubimceva T.¹; Topchyan A.²; Davtyan K.²; Poleschenko YA.³; Artiykhina E.⁴; Tarasiyk E.⁵; Kosonogov A.⁶; Kryzhanovsky D.⁷; Korolev S.⁸; Kolunin G.⁹; Sagitov I.¹⁰; Nechepurenko A.¹¹; Gasimova N.¹; Mikhaylov E.¹; Lebedev D.¹

¹Almazov National Medical Research Centre, Saint Petersburg, Russian Federation

²National Research Center for Preventive Medicine, Moscow, Russian Federation

³Saint Petersburg Pavlov State Medical University, Saint Petersburg, Russian Federation

⁴AV Vishnevsky Institute of Surgery, Moscow, Russian Federation

⁵Amur State Medical Academy, Blagoveshchensk, Russian Federation

⁶City Clinical Hospital 5, Nizhny Novgorod, Russian Federation

⁷26 Hospital, Saint Petersburg, Russian Federation

⁸State Clinical Hospital ? 86 FMBA, Moscow, Russian Federation

⁹Tyumen Cardiology Research Center, Tyumen, Russian Federation

¹⁰Republican Cardiology Clinic, Ufa, Russian Federation

¹¹Federal Center of Cardiovascular Surgery, Astrakhan, Russian Federation

OnBehalf: On Behalf Of the National Cryoballoon Registry Investigators

Background

Cryoballoon ablation (CBA) is an effective strategy for atrial fibrillation (AF) management. The Russian Cryoballoon Atrial Fibrillation Ablation Registry (NCT03040037) is a prospective observational multicenter national registry that aims to provide real-world efficacy, safety and outcomes of this technology.

Methods

A specialized Web-based registry platform was developed for prospective data entry. The platform consists of 8 sections: AF ablation clinic experience and operator experience, patient characteristics, CBA procedure characteristics, periprocedural patient management (including drug therapy), 12-moths follow-up with scheduled and unscheduled visits, redo procedure characteristics, early and late procedure-related complications. Patient inclusion criteria were the following: indications for AF catheter ablation, planned CBA, a signed informed consent.

Results


To date thirty-one clinics have joined the Registry, and 830 patients (477 males, a mean age 65.4 ± 11.3 years) were included. The mean BMI was 33.2 ± 3.3 kg/m². Paroxysmal AF was presented in 688 pts, persistent AF – 111 pts, long standing persistent AF – 31 pts. The main underlying diseases were hypertension (75%), coronary artery disease (11%), chronic heart failure (25%); less commonly - hypertrophic cardiomyopathy (1.4%) and dilated cardiomyopathy (0.7%). The mean LA diameter was 45.4 ± 10.2 mm, and LVEF was $65.4 \pm 12.6\%$.

Periprocedural anticoagulant therapy included: uninterrupted NOACs (313 pts), bridge anticoagulation (327 pts), uninterrupted warfarin (45 pts), anticoagulation initated only after CBA (32 pts). The mean temperature of cryoablation was -44.6 ± 16.3 C. Transesophageal echoguided CBA was performed in 92 cases , intracardiac echocardiography-guided - in 465 cases. There were 5 (0.6%) cases of hemopericardium, and pericardiocentesis was required in 1 (0.1%) case only. Periprocedural TIA was diagnosed in 1 (0.1%) patient with bridge anticoagulation, no stroke occurred. Transient phrenic nerve injury was detected in 18 (2.1%) patients, persistent palsy – in 1 (0.1%) patient. Two cases of esophageal injury were reported, no surgery was required and healing was reported in both patients. The data collection is ongoing.

Conclusion: We report early results of the ongoing national CBA Registry. There was a low number of major procedure-related adverse events in real clinical practice among centers with different AF ablation experience. Long-term follow up of the included patients will be reported in the future.

Abstract Figure. Antithrombotic therapy and CBA

Abstracts



Downloaded from https://academic.oup.com/europace/article/22/Supplement_1/euaa162.329/5858786 by guest on 25 April 2024